These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15851215)

  • 1. Language and interpretation of clinical trial outcomes: alternates, surrogates, and composites.
    Myerburg RJ; Castellanos A
    Heart Rhythm; 2004 Nov; 1(5):538-9. PubMed ID: 15851215
    [No Abstract]   [Full Text] [Related]  

  • 2. The delayed-start study in Parkinson disease: can't satisfy everyone.
    Olanow CW; Rascol O
    Neurology; 2010 Apr; 74(14):1149-50. PubMed ID: 20368635
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.
    Booth CM
    Clin Cancer Res; 2010 Dec; 16(24):5963-71. PubMed ID: 21169249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of study design on recruitment of patients to a primary care trial: an observational time series analysis of the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study.
    Fletcher K; Mant J; Roalfe A; Hobbs FD
    Fam Pract; 2010 Dec; 27(6):691-7. PubMed ID: 20610490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Introduction to randomized trials: the choice of endpoint].
    Simon EG; Fouché CJ; Perrotin F
    Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
    [No Abstract]   [Full Text] [Related]  

  • 6. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 7. [Methodological diversity in clinical research: an evaluation of the overall benefit for patients requires more than the randomised clinical trial].
    Koller M; Lorenz W; Abel U
    MMW Fortschr Med; 2006 Dec; 148(49-50):51. PubMed ID: 17619330
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized controlled trials in surgery: comic opera no more?
    Kassell NF; Dumont AS
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):243-4. PubMed ID: 16872942
    [No Abstract]   [Full Text] [Related]  

  • 9. Increasing the Impact of Randomized, Controlled Trials in Gastrointestinal Endoscopy.
    Elmunzer BJ
    Gastroenterology; 2015 Sep; 149(3):521-5. PubMed ID: 26226569
    [No Abstract]   [Full Text] [Related]  

  • 10. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269].
    Mant JW; Richards SH; Hobbs FD; Fitzmaurice D; Lip GY; Murray E; Banting M; Fletcher K; Rahman J; Allan T; Raftery J; Bryan S;
    BMC Cardiovasc Disord; 2003 Aug; 3():9. PubMed ID: 12939169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 12. Are there alternatives to mortality as an endpoint in clinical trials of atrial fibrillation?
    Wyse DG
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B41-4, discussion B44. PubMed ID: 15851138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
    Kirchhof P; Auricchio A; Bax J; Crijns H; Camm J; Diener HC; Goette A; Hindricks G; Hohnloser S; Kappenberger L; Kuck KH; Lip GY; Olsson B; Meinertz T; Priori S; Ravens U; Steinbeck G; Svernhage E; Tijssen J; Vincent A; Breithardt G
    Europace; 2007 Nov; 9(11):1006-23. PubMed ID: 17897925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical care services and trial methodology: even at the turning of the tide.
    Graf J; Janssens U
    Crit Care Med; 2007 Jun; 35(6):1620-2. PubMed ID: 17522539
    [No Abstract]   [Full Text] [Related]  

  • 16. Advanced issues in the design and conduct of randomized clinical trials: the bigger the better?
    Warlow C
    Stat Med; 2002 Oct; 21(19):2797-805. PubMed ID: 12325095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-inferiority study design: lessons to be learned from cardiovascular trials.
    Head SJ; Kaul S; Bogers AJ; Kappetein AP
    Eur Heart J; 2012 Jun; 33(11):1318-24. PubMed ID: 22564354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 19. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
    Sridhara R; Mandrekar SJ; Dodd LE
    Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.